You are here
Inflammation in the Pathophysiology of Benign Prostatic Hypertrophy
Jack A. Schalken
Department of Urology, Radboud University Medical Centre, Nijmegen, The Netherlands
Benign prostatic hyperplasia (BPH) is the most common urologic disease in elderly men, with an estimated prevalence of >70% at age 60 yr and >90% at age 70 yr [1,2]. BPH is a histologic diagnosis characterised by hyperproliferation of stromal and glandular cells in the transition zone and periurethral areas of the prostate gland [2,3]. The condition is often expressed clinically in the form of lower urinary tract symptoms (LUTS) [3,4]. Although several theories have been proposed to explain the progressive hyperplastic processes underlying BPH, the exact pathogenesis is not yet fully understood. Over the past decade in particular, accumulating evidence has suggested that inflammation contributes to the development and progression of prostatic hyperplasia . In this review, some earlier aetiological theories are revisited, and evidence for inflammation as a central component of BPH pathogenesis is examined.
2. Evidence acquisition
This article is based primarily on material presented at a satellite symposium entitled, “Inflammation and Prostatic Diseases: From Bench to Bedside,” held during the 2015 annual meeting of the European Association of Urology in Madrid, Spain. Current data regarding the link between inflammation and BPH were reviewed. The article is complemented by relevant related literature identified on PubMed and by hand searches of key references.
3. Evidence synthesis
3.1. Classical understanding of benign prostatic hyperplasia aetiology
Over the years, the classical understanding of BPH aetiology has centred around three main theories: the dihydrotestosterone (DHT) hypothesis, the embryonic reawakening theory, and the stem cell theory. Although each theory is not without some merit, none has been able to define the aetiologic trigger events responsible for progressive prostatic enlargement.
In the early 1980s, the prevailing assumption was that BPH resulted from an increased concentration of DHT, the most powerful androgen driving differentiation and growth in the early adult male. Although this hypothesis was ultimately proved incorrect, as DHT concentrations in prostate tissue actually decrease with age, 5α-reductase inhibitors were developed to treat BPH and continue to be prescribed with some success. Lending further support against the DHT hypothesis was the knowledge that DHT drives differentiation, not proliferation, in the prostate gland of an adult male. A defining event in the aging prostate gland is the increased ratio between prostatic oestradiol and DHT , which results in imbalance or disbalance in endocrine homeostasis.
During ontogenesis, epithelial buds arising from the urogenital sinus penetrate the surrounding mesenchyme and branch into the ductal system to form the primordium of the transition zone. After birth, prostatic morphogenesis reverts to the embryonic state . According to the embryonic reawakening theory, the embryonic potential to drive prostate morphogenesis is reawoken in adulthood. Although plausible, this theory simply redefines the question, as it fails to identify factors or mechanisms responsible for the reawakening.
The stem cell theory is arguably the most complex of the various hypotheses and is intertwined with embryonic reawakening. The morphogenic potential of the entire prostate epithelium is known to reside within a small fraction of adult stem cells . In BPH, it is proposed that epithelial growth results from alterations in stem cell properties which give rise to a clonal expansion of cell populations that develop into exocrine basal and luminal cells and neuroendocrine epithelial cells . Branching morphogenesis increases glandular structures, leading to prostatic enlargement. As with embryonic reawakening, however, this theory fails to identify the factors or mechanisms that underlie the “derailment” of stem cell expansion.
Although the classical model of BPH can be described in general terms as a disturbance in prostate homeostasis, the real question is why and how this disturbance occurs. The current understanding is that prostatic inflammation is either an initiating or a promoting event, but either way, the presence of inflammation explains many of the uncertainties in BPH models developed to date.
3.2. The role of inflammation in prostate abnormalities
Mahapokai and colleagues investigated the immune response in hormonally induced prostatic hyperplasia in the dog (the best-described model for human BPH identified to date)  and followed the process sequentially by biopsy . Marked infiltration with immune effector cells was observed. The majority of inflammatory cells (>80%) in the mononuclear infiltrates were T lymphocytes. B lymphocytes were found mainly in areas with marked follicular formation and diffuse infiltration, and macrophages were found primarily in areas with atrophic and cystic changes with and without inflammation. Longitudinal biopsy indicated that the cellmediated and humoral immune response was preceded by hyperplasia. In brief, hormonal disbalance as a primary event led to pronounced inflammation, and the processes appeared to work in concert. Regardless of whether inflammation was a cause, a consequence, or a crucial promoting factor in the prostatic enlargement and BPH progression observed in this model, it was a conspicuous component of the process.
Although human samples are typically more representative of a given disease than animal models, in the case of BPH, human specimens provide a single snapshot rather than longitudinal evaluation of the process over time. Notwithstanding this limitation, Robert and colleagues examined a large cohort of surgically treated BPH specimens to evaluate inflammation intensity and to investigate the relationship between inflammation and LUTS . A total of 227 prostatectomy specimens were used to build a tissue microarray of four spots per patient. A control tissue microarray was constructed using normal prostatic tissue samples from 10 donors after death. The inflammation score was determined on the basis of six cytologic parameters (lymphocytes, macrophages, polynuclear leukocyte infiltrates, glandular atrophy, glandular destruction, and tissue fibrosis) and five immunohistochemistry markers: CD3 antibody for T lymphocytes, CD4 antibody for T4, CD8 antibody for T8, CD20 antibody for B lymphocytes, and CD163 antibody for macrophages. The median inflammation level was used to divide patients into two groups (high and low levels).
A significant increase in inflammatory processes was observed, with good correlation between cytology and immunohistochemistry (r = 0.772; p < 0.0001). Significant prostatic inflammation was recorded in 73% of surgically treated BPH specimens versus 20% of specimens from donors after death (Fig. 1). A high level of inflammation was associated significantly with greater prostate volume (104 vs 90 g; p = 0.002) and a higher mean International Prostate Symptom Score (21.2 vs 12.8; p = 0.02). No differences were observed between high- and low-level inflammation groups for age, prostate-specific antigen level, or uroflowmetry. The inflammatory infiltrate consisted of 37.4% macrophages, 37% T lymphocytes (two-thirds T8 and one-third T4), and 12.9% B lymphocytes. Although an inflammation diagnosis was considered feasible on biopsy cores using either cytologic or immunohistochemical techniques, for clinical purposes, the author identified the need for less invasive diagnostic methods such as biomarkers .
The presence of inflammation as a component of BPH has been confirmed in both a canine model and human prostate tissue. Clinical questions that arise are whether inflammation is a key factor in BPH progression and/or a potential actionable target for BPH therapy.
Known causes of inflammation include infectious agents, cell trauma due to oxidative stress, hypoxia, autoimmunity, and endocrine changes. Aging-related visceral fat accumulation may initiate or contribute to inflammation through the secretion of inflammatory adipokines . In the case of BPH pathogenesis, the current hypothesis is that, whether cause or consequence, chronic inflammation is likely to be part of a domino effect (Fig. 2). Chronic inflammation and endocrine changes lead to disturbed homeostasis and tissue damage that, in turn, lead to compensatory cellular proliferation. Alternatively, it is possible that abnormal stem cell expansion and disturbed homeostasis lead to chronic inflammation and endocrine changes. Either way, a vicious cycle is initiated that leads to hyperplasia along with fibrosis and changes in tissue composition. Although the hypothesis requires confirmation, it already provides an interesting and testable model about the role of inflammation in the development and progression of BPH.
Fig. 1 – Incidence of prostatic inflammation in prostatectomy specimens from controls (donors after death) and patients with symptomatic benign prostatic hyperplasia . BPH = benign prostatic hyperplasia.
Fig. 2 – Proposed mechanism for the aetiology of benign prostatic hyperplasia. Inflammation is part of a “vicious cycle” of glandular changes that lead to alterations in prostate tissue volume and architecture.
Current understanding of BPH aetiology suggests that gradual endocrine changes and chronic inflammation disturb prostate homeostasis, particularly the interaction between stroma and epithelium; the stroma harbours the infectious components. Glandular changes lead to alterations in tissue architecture and often volume. Consequently, restoring tissue endocrine metabolism and reducing chronic inflammation are prostate-specific targets for the treatment of BPH. As knowledge of the disease processes steadily improves, it is becoming increasingly clear that BPH is much more than an enlarged prostate.
Conflicts of Interest
The author has nothing to disclose.
Participation in the satellite symposium, “Inflammation and Prostatic Diseases: From Bench to Bedside,” held at the annual meeting of the European Association of Urology in Madrid, Spain (March 2015), was sponsored by Pierre Fabre (Castres, France). Writing assistance was funded by Pierre Fabre.
Writing assistance was provided by Content Ed Net (Madrid, Spain).
 Bushman W. Etiology, epidemiology, and natural history of benign prostatic hyperplasia. Urol Clin North Am 2009;36:403–15.
 Chughtai B, Lee R, Te A, Kaplan S. Role of inflammation in benign prostatic hyperplasia. Rev Urol 2011;13:147–50.
 Untergasser G, Madersbacher S, Berger P. Benign prostatic hyperplasia: age-related tissue-remodeling. Exp Gerontol 2005;40:121–8.
 Nickel JC. Inflammation and benign prostatic hyperplasia. Urol Clin North Am 2008;35:109–15; vii.
 Bostanci Y, Kazzazi A, Momtahen S, Laze J, Djavan B. Correlation between benign prostatic hyperplasia and inflammation. Curr Opin Urol 2013;23:5–10.
 Roberts RO, Jacobson DJ, Rhodes T, Klee GG, Leiber MM, Jacobsen SJ. Serum sex hormones and measures of benign prostatic hyperplasia. Prostate 2004;61:124–31.
 Cai Y. Benign prostatic hyperplasia is a reawakened process of persistent Müllerian duct mesenchyme. BJU Int 2001;87:177–82.
 Xue Y, Smedts F, Verhofstad A, Debruyne F, de la Rosette J, Schalken J. Cell kinetics of prostate exocrine and neuroendocrine epithelium and their differential interrelationship: new perspectives. Prostate Suppl 1998;8:62–73.
 Prajapati A, Gupta S, Mistry B, Gupta S. Prostate stem cells in the development of benign prostate hyperplasia and prostate cancer: emerging role and concepts. Biomed Res Int 2013;2013:107954.
 Mahapokai W, Van Sluijs FJ, Schalken JA. Models for studying benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 2000;3:28–33.
 Mahapokai W, van den Ingh TS, van Mil F, et al. Immune response in hormonally-induced prostatic hyperplasia in the dog. Vet Immunol Immunopathol 2001;78:297–303.
 Robert G, Descazeaud A, Nicolaïew N, et al. Inflammation in prostatic tissue is associated with symptomatic BPH, IPSS and prostate volume! [abstract 1410]. J Urol 2009;181(Suppl):504.
 Robert G, Descazeaud A, Allory Y, Vacherot F, de la Taille. Should we investigate prostatic inflammation for the management of benign prostatic hyperplasia? Eur Urol Suppl 2009;8:879–86.
 Adams JD, Lien EJ, Wang X. Saw palmetto, Serenoa repens, in the treatment of benign prostatic hyperplasia, mechanisms of action and reasons for its use. Pharm Pharmacol Int J 2015;2:00007.
© 2015 European Association of Urology. Published by Elsevier B.V. All rights reserved.